Action EUCI EUROCINE VACCINES AB
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Eurocine Vaccines AB

Actions

EUCI

SE0015382155

Cours en clôture NORDIC GROWTH MARKET
Autres places de cotation
 00:00:00 20/06/2024 		Varia. 5j. Varia. 1 janv.
0,036 SEK +2,86% Graphique intraday de Eurocine Vaccines AB +4,65% -21,74%
30/05 Eurocine Vaccines AB (publ) annonce ses résultats pour le troisième trimestre et les neuf mois clos le 31 mars 2024 CI
28/02 Eurocine Vaccines AB (publ) annonce ses résultats pour le deuxième trimestre et le semestre clos le 31 décembre 2023 CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Eurocine Vaccines AB Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024
Eurocine Vaccines AB Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023
Certain Shares of Eurocine Vaccines AB are subject to a Lock-Up Agreement Ending on 15-FEB-2024.
Correction - Eurocine Vaccines discloses interim report for July - September 2023
Eurocine Vaccines AB Reports Earnings Results for the First Quarter Ended September 30, 2023
Eurocine Vaccines discloses interim report for Juli - September 2023
Eurocine Vaccines AB Reports Earnings Results for the Fourth Quarter Ended June 30, 2023
Eurocine Vaccines AB Reports Earnings Results for the Fourth Quarter and Full Year Ended June 30, 2023
Eurocine Vaccines discloses interim report for July 2022 - March 2023
Eurocine Vaccines AB Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023
Eurocine Vaccines Wins SEK300,000 Grant from Merck KGaA
Certain Shares of Eurocine Vaccines AB are subject to a Lock-Up Agreement Ending on 17-APR-2023.
Eurocine Vaccines discloses half-year report for July - December 2022
Eurocine Vaccines AB Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022
Eurocine Vaccines to Develop Chlamydia Vaccine Candidate Using mRNA
Eurocine Vaccines decides to develop mRNA-based vaccine candidate against chlamydia
Eurocine Vaccines AB Decides to Develop mRNA-Based Vaccine Candidate Against Chlamydia
Outstanding results for Eurocine Vaccines' mRNA based HSV-2 candidate
Eurocine Vaccines : Outstanding results for Eurocine Vaccines´ mRNA based HSV-2 candidate
Eurocine Vaccines AB Reports Earnings Results for the First Quarter Ended September 30, 2022
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action EUCI
  4. Actualités Eurocine Vaccines AB
  5. Autres langues